Search 

Medxense offers accurate continuous glucose monitoring for the intensive care unit (ICU). Normalization of patient blood glucose allows hospitals to reduce mortality and patient length of stay. 

The patented sensor technology platform is the only in the field to offer both high accuracy and near-instantaneous measurements in the hypoglycemic range, necessary for safe normalization of blood glucose.

We are now looking for an investment of 3 MUSD to fund clinical trials in the 2nd half of 2014. Expected exits are trade sale or IPO.

SpinChip Diagnostics will market the new state of the art platform for in vitro diagnostics (IVD) point of care (PoC) analysis. The technology will provide significant value by enabling faster, easier and more reliable PoC analysis at hospitals and in decentralized medical settings.